Which is the better dividend stock: Royal Dutch Shell plc or GlaxoSmithKline plc?

Royal Dutch Shell plc (LON: RDSB) and GlaxoSmithKline plc (LON: GSK) are two of the most popular dividend stocks, but does one have stronger dividend prospects?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Royal Dutch Shell (LSE: RDSB) and GlaxoSmithKline (LSE: GSK) are two of the most popular dividend stocks in the FTSE 100 index. I own both in my own portfolio. However, neither Shell nor Glaxo are perfect dividend stocks, in my view. Both have struggled with profitability in recent years, and as a result, have not increased their payouts. Today, I’m comparing the two companies. Is one a better dividend stock than the other?

Dividend yield

Beginning the analysis by looking at each company’s yield reveals that GlaxoSmithKline has a higher dividend yield than Shell right now. Shell paid its shareholders $1.88 in dividends last year, a yield of 5.9% at the current share price and exchange rate. Glaxo paid investors 80p per share, a yield of 6.2%. The healthcare giant wins here.

5 Stocks For Trying To Build Wealth After 50

One notable billionaire made 99% of his current wealth after his 50th birthday. And here at The Motley Fool, we believe it is NEVER too late to start trying to build your fortune in the stock market. Our expert Motley Fool analyst team have shortlisted 5 companies that they believe could be a great fit for investors aged 50+ trying to build long-term, diversified portfolios.

Click here to claim your free copy now!

Recent dividend growth

Examining recent dividend growth, between 2014 and 2016, Shell paid shareholders $1.88, $1.88 and $1.88. No growth was recorded, however, with the pound having fallen against the dollar, UK investors will have enjoyed a rise in the yield. In comparison, Glaxo, which declares its payout in GBP, paid 80p, 80p and 80p in that time. Again, no growth. However, the company did pay a special dividend of 20p per share in 2015. On that basis, I’ll give Glaxo the win in this department too. 

Dividend cover

City analysts expect Shell to generate earnings per share of $2 this year. That gives a dividend coverage ratio of just 1.06 times last year’s payout. In comparison, analysts expect Glaxo’s earnings to come in at 111p. That gives a coverage ratio of 1.39 times last year’s payout. Glaxo has the upper hand here, although neither ratio is strong. 


GlaxoSmithKline shares are also cheaper than Shell shares right now. The healthcare specialist sports a forward looking P/E ratio of just 11.8, vs 15.9 for Shell.

So far, Glaxo looks to be the better dividend stock. However, I’m not entirely convinced that it is.

Dividend outlook

The reason I say this is that Shell appears to have momentum at the moment. The oil price is back up to around $60 per barrel, and at that price, Shell can generate decent levels of free cash flow. With the merger of BG Group complete, Shell’s dividend is looking more and more sustainable, assuming the oil price doesn’t crash again. The stock’s 10% gain over the last three months reflects this.

In contrast, I’m getting more concerned about the sustainability of Glaxo’s dividend. Free cash flow is low, and with the group looking at potential acquisitions such as that of Pfizer, there could be implications for the payout.

When asked recently whether such a deal would carry dividend risk, CEO Emma Walmsley replied: “We confirmed our intentions to pay the dividend in 2017 of 80 pence and again in 2018 and then we will be returning to declaring the dividend quarterly and not giving a more specific outlook beyond that.”

Lack of long-term dividend assurance has rattled investors, with the stock falling 15% over the last three months. The market clearly has doubts about the sustainability of GlaxoSmithKline’s dividend.

So while Glaxo has the lower valuation, higher yield and better coverage, if I was to pick one dividend stock between the two right now, I’d be inclined to go with Shell. I believe there’s less chance of a dividend cut with Shell, assuming the oil price doesn’t plummet again. 

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Edward Sheldon owns shares in Royal Dutch Shell and GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Royal Dutch Shell B. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Senior woman wearing glasses using laptop at home
Investing Articles

SSE shares are up 15% since the market correction! Should I buy?

Jabran Khan looks at why SSE shares have been on an upward trajectory in recent weeks and decides if he…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

After crashing 29%, Spectris shares look cheap to me

After peaking at 4,167p last September, Spectris shares have slumped by over 29%. But I see deep value in the…

Read more »

British Pennies on a Pound Note
Investing Articles

Here is why I added this dirt-cheap FTSE 100 penny stock to my holdings!

Jabran Khan explains why he added this dirt-cheap FTSE 100 stock to his holdings and is excited by its recovery…

Read more »

Woman looking at a jar of pennies
Investing Articles

3 FTSE 100 penny stocks! Which is the cheapest buy?

Our writer examines three penny stocks that feature in the FTSE 100 index to ascertain whether they have a place…

Read more »

Arrowings ascending on a chalkboard
Investing Articles

Is the Vodafone share price an opportunity at current levels?

Jabran Khan looks at the current Vodafone share price and decides if he would add the shares to his holdings…

Read more »

Smiling senior white man talking through telephone while using laptop at desk.
Investing Articles

4 gems I’d include in my Stocks & Shares ISA

Jon Smith explains some of the top stocks he's thinking about including in his Stocks and Shares ISA a we…

Read more »

Compass pointing towards 'best price'
Investing Articles

At 85p, are Rolls-Royce shares a no-brainer buy? 

The Rolls-Royce share price look very cheap right now. And I think this might be my last chance to buy…

Read more »

positive mental health woman
Investing Articles

My £3-a-day blue-chip passive income plan

Our writer sets out his passive income plan of investing a few pounds each day in top stocks.

Read more »